Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) delivers cutting-edge gene therapies targeting rare central nervous system disorders through innovative AAV vector technology. This news hub provides investors and researchers with timely updates on clinical advancements, strategic partnerships, and operational developments shaping the company's trajectory in genetic medicine.
Access authoritative reporting on PASG's lead programs including PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia. Our curated news collection features regulatory milestones, trial data disclosures, and analysis of licensing agreements with academic and industry partners.
Key updates cover three critical areas: clinical trial progress across neurodegenerative targets, research collaborations enhancing therapeutic platforms, and strategic operational decisions supporting sustainable development. Bookmark this page for consolidated access to PASG's evolving position in gene therapy innovation.
Passage Bio (Nasdaq: PASG) will present updated data from its Phase 1/2 upliFT-D clinical trial of PBFT02, a gene therapy for frontotemporal dementia (FTD) with granulin mutations, at the 14th International Conference on Frontotemporal Dementias on September 20, 2024. The interim results from Cohort 1 (n=5) show that Dose 1 of PBFT02 was well-tolerated in patients receiving an enhanced immunosuppression regimen, with no serious adverse events observed.
Key findings include:
- Robust and durable increase in CSF progranulin (PGRN) expression, up to 6-fold at one month and 10-fold at six months
- CSF PGRN levels exceeded healthy adult control ranges
- Elevated CSF PGRN levels sustained up to 12 months post-treatment
- No evidence of dorsal root ganglion toxicity or clinically significant immune responses
These results suggest PBFT02's potential as a best-in-class progranulin-raising therapy for neurodegenerative diseases.
Passage Bio (Nasdaq: PASG) has appointed Tom Kassberg to its Board of Directors and Audit Committee. Kassberg, currently Chief Business Officer and Executive VP at Ultragenyx, brings extensive experience in strategic planning and corporate development. His background includes leadership roles at Proteolix, InterMune, Plexxikon, and SUGEN. Passage Bio CEO Will Chou highlighted Kassberg's expertise in advancing gene therapies for rare diseases, which aligns with the company's focus on neurodegenerative diseases. Kassberg expressed enthusiasm for joining Passage Bio, particularly noting the progress of the PBFT02 program and its potential expansion into additional indications.
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company focusing on neurodegenerative diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's president and CEO, Will Chou, M.D., is scheduled to present on Monday, September 9, 2024, at 7:00 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through the Investors & Media section of Passage Bio's website at investors.passagebio.com. For those unable to attend the live event, a replay will be available for 30 days following the presentation.
Passage Bio (Nasdaq: PASG) reported Q2 2024 financial results and business highlights. Key points include:
- Enrolled first FTD-GRN patient in Cohort 2 of upliFT-D trial
- FDA agreed to expand upliFT-D trial to include FTD-C9orf72 patients
- Out-licensed pediatric lysosomal storage disease programs to GEMMA Biotherapeutics
- Cash runway extended to end of Q2 2026
- Q2 2024 financials: $91.8M cash position, $10.4M R&D expenses, $6.5M G&A expenses, $16.0M net loss ($0.26 per share)
The company plans to present updated safety and biomarker data from Cohort 1 FTD-GRN patients at ISFTD2024 in September 2024 and expects to initiate dosing of FTD-C9orf72 patients in 1H 2025.
Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, has announced its participation in two upcoming investor conferences. The company will be present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024, in Boston, MA, where management will give a presentation at 8:00 a.m. ET and participate in investor meetings. Additionally, Passage Bio will attend the 15th Annual Wedbush PacGrow Healthcare Conference on August 14, 2024, in New York City, NY, participating in investor meetings.
A live webcast of the Canaccord Genuity conference presentation will be available on the Investors & Media section of Passage Bio's website, with a replay accessible for 30 days following the event. This participation in investor conferences demonstrates Passage Bio's commitment to engaging with the investment community and sharing updates on their progress in developing treatments for neurodegenerative diseases.
Passage Bio (NASDAQ: PASG) has out-licensed three pediatric gene therapy programs to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson. The deal includes exclusive, worldwide rights for PBGM01 (GM1 gangliosidosis), PBKR03 (Krabbe disease), and PBML04 (metachromatic leukodystrophy). Passage Bio will receive initial payments of $10 million, with potential for up to $124 million in additional milestones and future royalties.
The company also entered a new strategic research collaboration with GEMMA Biotherapeutics, focusing on CNS indications including Huntington's disease. This transaction is expected to extend Passage Bio's operating cash runway to the end of Q2 2026, allowing the company to focus on advancing its lead asset, PBFT02, in multiple adult neurodegenerative diseases.
Passage Bio (NASDAQ: PASG) has received positive feedback from the FDA on expanding its upliFT-D trial of PBFT02 to include FTD-C9orf72 patients. The company plans to amend the ongoing Phase 1/2 global study protocol to introduce this new patient population, with dosing expected to begin in 1H 2025. This expansion is supported by compelling preclinical evidence and safety data from the first cohort of FTD-GRN patients treated with PBFT02.
FTD-C9orf72 affects approximately 21,000 individuals in the US and Europe. The FDA has granted PBFT02 Fast Track and Orphan Drug designations, while the European Commission has also given it Orphan designation. This development could bring new hope to an underserved patient community with clinical trial options.
Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, will present at the Goldman Sachs 45th Annual Global Healthcare Conference. President and CEO William Chou, M.D., will deliver the presentation on June 12, 2024, at 4:00 p.m. ET. The live webcast and a 30-day replay will be accessible on Passage Bio's website.
Passage Bio (Nasdaq: PASG), a clinical stage genetic medicines company, announced Carrie Gordon, a sophomore at Drexel University, as the third recipient of its Tachi Yamada Scholarship. This award honors Dr. Tachi Yamada, the co-founder and former Chairman, and supports life sciences students in Pennsylvania. Carrie, pursuing a degree in Biological Science with a minor in Neuroscience, has a passion for neurology and aims to provide healthcare to underserved communities. The scholarship provides financial assistance and a mentor from Passage Bio for professional growth.
Passage Bio (NASDAQ: PASG) reported its Q1 2024 financial results and provided business updates, including advances in its global upliFT-D clinical trial for FTD-GRN. The trial's Dose 1 PBFT02 consistently elevated CSF progranulin at six months in two patients. All five patients in Cohort 1 have been dosed, with safety and biomarker data expected in 2H 2024. Cohort 2 dosing is planned to start by the end of 1H 2024. The company initiated discussions with the FDA for using PBFT02 to treat FTD-C9orf72, with feedback expected in 2H 2024. Financially, the company ended Q1 with $104.5 million in cash, projecting a cash runway into Q4 2025. Net loss decreased to $16.7 million from $34.3 million year-over-year.
FAQ
What is the current stock price of Passage Bio (PASG)?
What is the market cap of Passage Bio (PASG)?
